News & Updates

Treatment with isoniazid and rifapentine (HP) either for 1 month daily (1HP) or 3 months weekly (3HP) results in high rates of treatment success among people with a positive latent tuberculosis infection test and without HIV infection, a study has shown. The 3HP regimen has slightly lower rates of adverse reactions, but neither exhibits superiority to the other.

In the secondary analysis of the REPRIEVE trial presented at CROI 2026, pitavastatin reduced the risk of developing incident hypertension in people living with HIV (PLWH).

The phase II/III open-label ARTISTRY-1 trial shows that people living with HIV (PWH) may simplify their complex regimen (CR) by switching to a novel daily single-tablet regimen (STR) comprising bictegravir and lenacapavir (BIC+LEN).

Timely and effective rehabilitation interventions can improve orthodeoxia and functional outcome in patients with COVID-19-related platypnoea‒orthodeoxia syndrome (POS), suggests a Singapore study.